| URL | Priority | Change frequency | Last modified (GMT) |
|---|---|---|---|
| https://altaioncology.com/new-protocol-pembrolizumab-chemotherapy-for-previously-untreated-advanced-triple-negative-breast-cancer-2/ | 60% | Monthly | 2020-12-16 02:38 |
| https://altaioncology.com/new-protocol-pembrolizumab-chemotherapy-for-previously-untreated-advanced-triple-negative-breast-cancer/ | 60% | Monthly | 2020-12-16 02:38 |
| https://altaioncology.com/new-indication-axitinib-for-unresectable-recurrent-or-metastatic-head-and-neck-cancer-2/ | 60% | Monthly | 2020-12-16 02:38 |
| https://altaioncology.com/new-protocol-venetoclax-600-daily-cytarabine-20-mg-subq-d1-10-28d-for-acute-myeloid-leukemia-2/ | 60% | Monthly | 2020-12-16 02:39 |
| https://altaioncology.com/new-indication-tazemetostat-for-relapsed-refractory-follicular-lymphoma-2/ | 60% | Monthly | 2020-12-23 07:48 |
| https://altaioncology.com/new-indication-axitinib-for-unresectable-recurrent-or-metastatic-head-and-neck-cancer/ | 60% | Monthly | 2020-12-16 02:39 |